AbbVie dumps an early-stage drug in $225M Alzheimer's alliance with Alector
Back in November, as Biogen and the controversy surrounding Aduhelm soaked up the attention around Alzheimer’s R&D, Alector quietly presented Phase I data for an AbbVie-partnered program at the annual conference for Clinical Trials on Alzheimer’s Disease. At the time, Alector said a Phase II trial was being planned for the second half of 2022.
A few weeks ago, though, Alector told investors that it’s “currently reviewing potential next steps for the AL003 program together with AbbVie.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.